Annals of Clinical and Translational Neurology (May 2023)

Lorlatinib for ALK‐fused, infant‐type hemispheric glioma with lung metastasis: a case report

  • Mingyao Lai,
  • Shaoqun Li,
  • Hainan Li,
  • Qingjun Hu,
  • Juan Li,
  • Jiangfen Zhou,
  • Ruyu Ai,
  • Junjie Zhen,
  • Zhaoming Zhou,
  • Lichao Wang,
  • Yangqiong Zhang,
  • Wanming Hu,
  • Li Yuan,
  • Xuejiao Ma,
  • Xing Zhang,
  • Chao Song,
  • Zhi Li,
  • Linbo Cai

DOI
https://doi.org/10.1002/acn3.51766
Journal volume & issue
Vol. 10, no. 5
pp. 836 – 841

Abstract

Read online

Abstract Infant‐type hemispheric glioma, a new subtype of pediatric high‐grade glioma, arises in the cerebral hemispheres. Despite better survival outcomes, the treatment of infant‐type hemispheric glioma is still facing challenges. Here, we reported a case of QKI‐ALK fusion, infant‐type hemispheric glioma with lung metastasis who achieved a complete clinical response after lorlatinib treatment. This typical case demonstrated the importance of appropriate molecularly targeted treatments in ALK‐fused tumors, and lorlatinib may serve as an effective complement to conventional chemotherapy and radiotherapy in primary glioma harboring ALK fusions and its metastasis.